文献速递流行病学与生物统计基础与转化研究

汇总数据与个体参与者数据Meta分析在随机试验中的比较:一项观察性研究

Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study.
PubMed 文献 · PLoS Med · 2020-01-31

该观察性研究基于18项包含个体参与者数据(IPD)Meta分析的癌症系统综述,比较了已发表汇总数据(AD)与IPD在试验和Meta分析层面得出的生存风险比(HR)。研究发现AD来源的HR平均略偏向研究干预,但信息量(参与者数或事件数)较大时两者一致性更好,并据此构建了判断AD Meta分析信息是否充分的决策树。

要点

  • 当AD信息量较大时,其HR与IPD等效HR更可能一致。
  • AD来源的试验HR平均略偏向研究干预(HRAD/HRIPD=0.95,p=0.007)。
  • 即使信息量大,单个Meta分析HR仍可与IPD相差相对10%至5%。

核心结论

  • 已发表AD的HR在信息量较大时最可能与IPD一致。
  • 基于结果提供了判断AD Meta分析何时可靠的决策树。

研究设计与样本

  • 观察性研究,纳入18项MRC临床试验单元Meta分析组1991至2010年完成的癌症系统综述。
  • 共238项独特试验或试验比较,含37,082名参与者。
  • 从试验报告中提取或估计HR与标准误,并与IPD对应值比较。

主要发现

  • 试验层面AD的HR平均略偏向研究干预(HRAD/HRIPD=0.95,p=0.007)。
  • AD与IPD的一致性界限随参与者数、事件数或事件比例增加而缩窄(均p<0.001)。
  • Meta分析层面固定效应模型HRAD/HRIPD=0.97(p=0.088),随机效应模型=0.96(p=0.044)。
  • 即使AD信息量大,单个Meta分析HR仍可与IPD相差相对10%偏向研究干预至5%偏向对照。

关键数值与推荐

  • 仅127项试验(占53%试验、约79%合格参与者)可生成HR和标准误。
  • 一致性界限随AD事件数增加(p=0.077)或事件比例增加(p=0.11)趋于缩窄。

临床怎么用

  • 信息量较大时,标准AD Meta分析可能提供稳健的临床结论。
  • 信息量不足或异质性大时,IPD方法可能增加价值。
  • 可参考决策树系统判断何时需要IPD Meta分析。

局限性

  • Meta分析层面把握度不足可能妨碍识别其他与AD Meta分析可靠性相关的因素。
  • 结果可能无法推广至所有结局和效应测量指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It remains unclear when standard systematic reviews and meta-analyses that rely on published aggregate data (AD) can provide robust clinical conclusions. We aimed to compare the results from a large cohort of systematic reviews and meta-analyses based on individual participant data (IPD) with meta-analyses of published AD, to establish when the latter are most likely to be reliable and when the IPD approach might be required. METHODS AND FINDINGS: We used 18 cancer systematic reviews that included IPD meta-analyses: all of those completed and published by the Meta-analysis Group of the MRC Clinical Trials Unit from 1991 to 2010. We extracted or estimated hazard ratios (HRs) and standard errors (SEs) for survival from trial reports and compared these with IPD equivalents at both the trial and meta-analysis level. We also extracted or estimated the number of events. We used paired t tests to assess whether HRs and SEs from published AD differed on average from those from IPD. We assessed agreement, and whether this was associated with trial or meta-analysis characteristics, using the approach of Bland and Altman. The 18 systematic reviews comprised 238 unique trials or trial comparisons, including 37,082 participants. A HR and SE could be generated for 127 trials, representing 53% of the trials and approximately 79% of eligible participants. On average, trial HRs derived from published AD were slightly more in favour of the research interventions than those from IPD (HRAD to HRIPD ratio = 0.95, p = 0.007), but the limits of agreement show that for individual trials, the HRs could deviate substantially. These limits narrowed with an increasing number of participants (p < 0.001) or a greater number (p < 0.001) or proportion (p < 0.001) of events in the AD. On average, meta-analysis HRs from published AD slightly tended to favour the research interventions whether based on fixed-effect (HRAD to HRIPD ratio = 0.97, p = 0.088) or random-effects (HRAD to HRIPD ratio = 0.96, p = 0.044) models, but the limits of agreement show that for individual meta-analyses, agreement was much more variable. These limits tended to narrow with an increasing number (p = 0.077) or proportion of events (p = 0.11) in the AD. However, even when the information size of the AD was large, individual meta-analysis HRs could still differ from their IPD equivalents by a relative 10% in favour of the research intervention to 5% in favour of control. We utilised the results to construct a decision tree for assessing whether an AD meta-analysis includes sufficient information, and when estimates of effects are most likely to be reliable. A lack of power at the meta-analysis level may have prevented us identifying additional factors associated with the reliability of AD meta-analyses, and we cannot be sure that our results are generalisable to all outcomes and effect measures. CONCLUSIONS: In this study we found that HRs from published AD were most likely to agree with those from IPD when the information size was large. Based on these findings, we provide guidance for determining systematically when standard AD meta-analysis will likely generate robust clinical conclusions, and when the IPD approach will add considerable value.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Tierney JF, Fisher DJ, Burdett S, et al. Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study. PLoS Med. 2020. PMID: 32004320. doi:10.1371/journal.pmed.1003019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。